Lyophilised peptides: what freeze-drying does and does not tell you

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

A lyophilised peptide is a peptide that has been freeze-dried: frozen, then dried under vacuum so that the ice turns directly into vapour, leaving a dry solid in the vial. Most research peptides are supplied this way because many peptides are less stable in solution than as a dry solid. The dried form tells you how the material was processed. It does not tell you what the peptide is, how pure it is or how much peptide the vial holds; only batch testing answers those questions.

What does lyophilised mean?

Lyophilisation is the technical name for freeze-drying. “Lyophilised” is the British spelling and “lyophilized” the American one; both describe the same process. The US Food and Drug Administration (FDA) inspection guide to lyophilisation describes it as three separate, unique and interdependent processes: freezing, primary drying (sublimation) and secondary drying (desorption).

A 2004 review in Pharmaceutical Research by Tang and Pikal sets out the science behind each stage. It discusses how ice formation during freezing affects the rest of the process and the final product, and why the product temperature during primary drying is chosen in relation to the collapse temperature, the point at which the frozen structure can no longer hold its shape. Most of this literature comes from the manufacture of medicines, especially protein products, but the physical principles are the same for a vial of synthetic peptide.

Why are research peptides supplied lyophilised?

Mainly for stability. The FDA guide states that products are manufactured in lyophilised form “due to their instability when in solution”. In water, a peptide is exposed to chemical reactions such as oxidation and deamidation and to physical changes such as aggregation, and removing most of the water slows many of these processes. A 2010 review of protein stability in Pharmaceutical Research covers both chemical and physical instability and deals with stabilisation in solution and in the dried state as separate problems.

Freeze-drying is not free of stress, though. A 2018 review of drying technologies in Pharmaceutics describes freeze-drying as the most common drying method for therapeutic proteins, and notes that the process applies freezing and dehydration stresses that may alter protein structure. That is why the process is designed around the product, and why a dried material still needs analytical checks.

Freeze-drying also fits the way synthetic peptides are made. A 2020 review of peptide counter-ions in Pharmaceuticals notes that cleavage and purification are usually carried out with trifluoroacetic acid (TFA), and that the acids commonly used in purification, apart from phosphoric acid, can be removed by lyophilisation. Counter-ions bound to the peptide itself are a different matter, and the review notes that cationic peptides are obtained as trifluoroacetate salts.

What is actually in a vial of lyophilised peptide?

More than peptide. The dry solid is usually a mixture, so the weight of the solid in a vial is not the same as the weight of peptide.

This matters for any calculation. An HPLC purity figure describes how the peptide-related material separates. It is not a measure of how much of the solid is peptide, because water and counterions are not part of that figure. Peptide content is a separate measurement, and consensus recommendations published in Clinical Chemistry in 2016 treat the generation, quantification, storage and handling of peptide standards as distinct steps. A 2014 review of related impurities in peptide medicines describes the synthesis- and degradation-related impurities that HPLC is there to separate. Our article on peptide counterions looks at the salt form in more detail.

Residual moisture: why “dry” is relative

Freeze-drying never removes every trace of water, and the amount left behind affects stability. The FDA guide expects manufacturers to have data supporting moisture specifications for both product release and stability.

A 2001 study in Pharmaceutical Research by Breen and colleagues shows why. They freeze-dried a humanised monoclonal antibody formulation at residual moisture levels from 1% to 8% and stored it at temperatures from 5 °C to 50 °C for six or twelve months. The glass transition temperature (Tg), the point at which the glassy solid starts to soften, fell from 80 °C at 1% moisture to 25 °C at 8%. Higher moisture reduced chemical stability whether the solid was glassy or rubbery. Physical stability behaved differently: it was not compromised, and may even have been better, at higher moisture as long as storage stayed below Tg.

Two lessons carry over to peptide work, with the caveat that the study used an antibody formulation, not a synthetic peptide. First, water content is a stability variable in its own right. Common laboratory practice is to limit water uptake after drying, for example by storing vials with a desiccant and letting a cold vial reach room temperature before opening it; these are general good-practice habits, not findings of the study. Second, the right moisture level belongs to a specific material and cannot be borrowed from another product.

What should a lyophilised peptide look like?

Freeze-dried material can appear as a solid “cake” at the bottom of the vial, a thin film on the glass or loose powder. Appearance depends on the formulation, the amount of solid and what happened in transit, and a cake that has broken up in the post is not necessarily a sign of degradation. A 2017 review in the Journal of Pharmaceutical Sciences by Patel and colleagues addressed exactly this question. It describes cake appearance as an important attribute “which may or may not be critical with respect to product quality”, and proposes a shared vocabulary for describing departures from the ideal uniform cake.

Some changes are still worth recording. The FDA guide singles out meltback, “a form of cake collapse” caused by a change from the solid to the liquid state. A shrunken, glassy or wet-looking cake, an unexpected change of colour, or a solid that has turned sticky or clumped can point to a manufacturing or storage problem and is worth raising with the supplier. Some colour is expected: copper complexes such as GHK-Cu are blue, as our KLOW article explains.

The reverse does not hold. A cake that looks perfect can still contain an oxidised or aggregated peptide, and the size of a cake says nothing about how much peptide it contains.

How to check a lyophilised peptide batch

The powder form is a starting point, not evidence. When a vial arrives, check:

• The batch number on the vial matches the batch laboratory report. You can look up any batch on our batch report lookup.
• Identity was confirmed by mass spectrometry, not just inferred from a retention time. See HPLC vs mass spectrometry.
• Purity is read as a description of the HPLC separation, not as peptide content. See 99% purity: what does that number actually tell you?
• The salt form and, where reported, water content are stated.
• The appearance on receipt is recorded with the date, so any later change can be compared against it.
• The storage conditions on the label are followed from the moment the vial is unpacked.

How should lyophilised peptides be stored?

The dry state is more forgiving than a solution, not immune to its surroundings. The International Council for Harmonisation (ICH) stability guideline Q1A(R2) describes stability testing as showing how quality “varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light”, and adds oxidation in stress testing. A 2017 review in Interface Focus lists lyophilisation itself, along with temperature and surfaces, among the factors that influence peptide aggregation.

In practice that means keeping vials sealed, dry, away from light and at the temperature on the label, and following the batch documentation for that material. Once a peptide is dissolved, the stability advantage of the dry state is lost. This article gives no guidance on dissolving peptides; follow your laboratory’s validated procedure. Our peptide storage guide covers moisture, temperature, light, oxygen and freeze–thaw in more detail.

Lyophilised peptide FAQs

What does lyophilised peptide mean?

A peptide that has been freeze-dried: frozen and then dried under vacuum so that the ice sublimes, leaving a dry solid. It describes the physical form, not the identity or purity of the material.

Is lyophilised the same as freeze-dried?

Yes. Lyophilisation is the technical term for freeze-drying. “Lyophilised” is the British spelling and “lyophilized” the American one.

Are lyophilised peptides more stable than peptides in solution?

Generally, yes. Freeze-drying is used because many products are unstable in solution, but a dry solid is still affected by moisture, temperature and light, so storage conditions matter.

Why does the powder look different from one vial to another?

Cake shape and volume depend on the formulation, the amount of solid and handling in transit, and they are not a measure of peptide content. Record anything that looks collapsed, wet or discoloured and raise it with the supplier.

Do lyophilised peptides need to be kept in the fridge?

There is no universal rule. Follow the storage temperature on the vial label and in the batch documentation for that material.

Sources

• US Food and Drug Administration. Lyophilization of Parenteral (7/93). Inspection guide.
• Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharmaceutical Research. 2004;21(2):191–200. Review.
• Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544–575. Review.
• Emami F, Vatanara A, Park EJ, Na DH. Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics. 2018;10(3):131. Review.
• Sikora K, Jaśkiewicz M, Neubauer D, et al. The role of counter-ions in peptides: an overview. Pharmaceuticals. 2020;13(12):442. Review.
• Hoofnagle AN, Whiteaker JR, Carr SA, et al. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clinical Chemistry. 2016;62(1):48–69. Consensus recommendations.
• D’Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. Review.
• Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharmaceutical Research. 2001;18(9):1345–1353. Primary study; antibody formulation.
• Patel SM, Nail SL, Pikal MJ, et al. Lyophilized drug product cake appearance: what is acceptable? Journal of Pharmaceutical Sciences. 2017;106(7):1706–1721. Review.
• International Council for Harmonisation. Q1A(R2): Stability testing of new drug substances and products. Step 4, 6 February 2003. Guideline.
• Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. Review.

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.